Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 367

1.

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.

Lluch A, González-Angulo AM, Casadevall D, Eterovic AK, Martínez de Dueñas E, Zheng X, Guerrero-Zotano Á, Liu S, Pérez R, Chen K, Chacón JI, Mills GB, Antolín S, Blancas I, López-Serra P, Carrasco E, Caballero R, Prat A, Rojo F, Gonzalez-Perez A, Meric-Bernstam F, Albanell J.

Eur J Cancer. 2019 Sep 3;120:54-64. doi: 10.1016/j.ejca.2019.07.003. [Epub ahead of print]

PMID:
31491604
2.

Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.

Liu ZB, Ezzedine NE, Eterovic AK, Ensor JE, Huang HJ, Albanell J, Choi DS, Lluch A, Liu Y, Rojo F, Wong H, Martínez-Dueñas E, Guerrero-Zotano Á, Shao ZM, Darcourt JG, Mills GB, Dave B, Chang JC.

Breast Cancer Res Treat. 2019 Aug 6. doi: 10.1007/s10549-019-05374-x. [Epub ahead of print]

PMID:
31388936
3.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562-3. doi: 10.1016/j.jtho.2019.07.005. [Epub ahead of print]

4.

Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids.

Fernández-Barral A, Costales-Carrera A, Buira SP, Jung P, Ferrer-Mayorga G, Larriba MJ, Bustamante-Madrid P, Domínguez O, Real FX, Guerra-Pastrián L, Lafarga M, García-Olmo D, Cantero R, Del Peso L, Batlle E, Rojo F, Muñoz A, Barbáchano A.

FEBS J. 2019 Jul 15. doi: 10.1111/febs.14998. [Epub ahead of print]

PMID:
31306552
5.

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC.

ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.

6.

Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).

García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J.

Oncologist. 2019 Jun 24. pii: theoncologist.2018-0728. doi: 10.1634/theoncologist.2018-0728. [Epub ahead of print]

PMID:
31235483
7.

Evaluation of Neurosecretome from Mesenchymal Stem Cells Encapsulated in Silk Fibroin Hydrogels.

Martín-Martín Y, Fernández-García L, Sanchez-Rebato MH, Marí-Buyé N, Rojo FJ, Pérez-Rigueiro J, Ramos M, Guinea GV, Panetsos F, González-Nieto D.

Sci Rep. 2019 Jun 19;9(1):8801. doi: 10.1038/s41598-019-45238-4.

8.

Diabetes-mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction.

Del Puerto-Nevado L, Santiago-Hernandez A, Solanes-Casado S, Gonzalez N, Ricote M, Corton M, Prieto I, Mas S, Sanz AB, Aguilera O, Gomez-Guerrero C, Ayuso C, Ortiz A, Rojo F, Egido J, Garcia-Foncillas J, Minguez P, Alvarez-Llamas G; DiabetesCancerConnect Consortium.

Mol Oncol. 2019 Sep;13(9):1887-1897. doi: 10.1002/1878-0261.12531. Epub 2019 Jul 27.

9.

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.

Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M.

Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12.

PMID:
31189644
10.

Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.

Hernández-Prat A, Rodriguez-Vida A, Juanpere-Rodero N, Arpi O, Menéndez S, Soria-Jiménez L, Martínez A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J.

Mol Cancer Res. 2019 Sep;17(9):1931-1944. doi: 10.1158/1541-7786.MCR-18-0923. Epub 2019 Jun 3.

PMID:
31160383
11.

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z.

12.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M.

Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30.

13.

Post-translational regulation could determine functional differences between SET alpha and beta isoforms in chronic lymphocytic leukaemia.

Cristóbal I, Sanz-Alvarez M, Luque M, Rojo F, García-Foncillas J.

Br J Haematol. 2019 Aug;186(4):638. doi: 10.1111/bjh.15935. Epub 2019 Apr 24. No abstract available.

PMID:
31020656
14.

Combining electrokinetic transport and bioremediation for enhanced removal of crude oil from contaminated marine sediments: Results of a long-term, mesocosm-scale experiment.

Cappello S, Cruz Viggi C, Yakimov M, Rossetti S, Matturro B, Molina L, Segura A, Marqués S, Yuste L, Sevilla E, Rojo F, Sherry A, Mejeha OK, Head IM, Malmquist L, Christensen JH, Kalogerakis N, Aulenta F.

Water Res. 2019 Jun 15;157:381-395. doi: 10.1016/j.watres.2019.03.094. Epub 2019 Apr 3.

PMID:
30974287
15.

Letter by Cristóbal et al Regarding Article, "Protein Phosphatase 2A Regulates Cardiac Na+ Channels".

Cristóbal I, Sanz-Alvarez M, Luque M, Rojo F, García-Foncillas J.

Circ Res. 2019 Apr 12;124(8):e59. doi: 10.1161/CIRCRESAHA.119.314905. No abstract available.

PMID:
30973817
16.

Pseudomonas putida KT2440 metabolism undergoes sequential modifications during exponential growth in a complete medium as compounds are gradually consumed.

Molina L, Rosa R, Nogales J, Rojo F.

Environ Microbiol. 2019 Jul;21(7):2375-2390. doi: 10.1111/1462-2920.14622. Epub 2019 Apr 21.

PMID:
30951237
17.

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P.

Sci Rep. 2019 Mar 29;9(1):5316. doi: 10.1038/s41598-019-41472-y.

18.

The Role of MicroRNAs in Hepatoblastoma Tumors.

Cristóbal I, Sanz-Álvarez M, Luque M, Caramés C, Rojo F, García-Foncillas J.

Cancers (Basel). 2019 Mar 22;11(3). pii: E409. doi: 10.3390/cancers11030409. Review.

19.

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer.

Cristóbal I, Torrejón B, Rubio J, Santos A, Pedregal M, Caramés C, Zazo S, Luque M, Sanz-Alvarez M, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

J Clin Med. 2019 Mar 12;8(3). pii: E346. doi: 10.3390/jcm8030346.

20.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Erratum in: Sci Rep. 2019 May 17;9(1):7706.

21.

Molecular evidence of field cancerization initiated by diabetes in colon cancer patients.

Del Puerto-Nevado L, Minguez P, Corton M, Solanes-Casado S, Prieto I, Mas S, Sanz AB, Gonzalez-Alonso P, Villaverde C, Portal-Nuñez S, Aguilera O, Gomez-Guerrero C, Esbrit P, Vivanco F, Gonzalez N, Ayuso C, Ortiz A, Rojo F, Egido J, Alvarez-Llamas G, Garcia-Foncillas J; DiabetesCancerConnect Consortium.

Mol Oncol. 2019 Apr;13(4):857-872. doi: 10.1002/1878-0261.12438. Epub 2019 Feb 16.

22.

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.

Ocana A, Gil-Martin M, Antolín S, Atienza M, Montaño Á, Ribelles N, Urruticoechea A, Falcón A, Pernas S, Orlando J, Montero JC, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A, Ruiz-Borrego M.

Breast Cancer Res Treat. 2019 Apr;174(3):693-701. doi: 10.1007/s10549-018-05100-z. Epub 2019 Jan 3.

PMID:
30607629
23.

Religiosity and health: A global comparative study.

Zimmer Z, Rojo F, Ofstedal MB, Chiu CT, Saito Y, Jagger C.

SSM Popul Health. 2018 Nov 15;7:006-6. doi: 10.1016/j.ssmph.2018.11.006. eCollection 2019 Apr.

24.

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival.

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, López-Botet M, Albanell J.

Clin Cancer Res. 2019 Mar 1;25(5):1535-1545. doi: 10.1158/1078-0432.CCR-18-2365. Epub 2018 Dec 6.

PMID:
30523021
25.

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma.

Nájera L, Alonso-Juarranz M, Garrido M, Ballestín C, Moya L, Martínez-Díaz M, Carrillo R, Juarranz A, Rojo F, Cuezva JM, Rodríguez-Peralto JL.

Br J Dermatol. 2019 Jul;181(1):114-127. doi: 10.1111/bjd.17513. Epub 2019 Mar 18.

PMID:
30537064
26.

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.

García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, López R, Muinelo-Romay L, Montagut C, Antón A, López G, Díaz-Rubio E, Rojo F, Vivancos A.

Br J Cancer. 2018 Dec;119(12):1464-1470. doi: 10.1038/s41416-018-0293-5. Epub 2018 Nov 23.

27.

Novel regulatory mechanism of establishment genes of conjugative plasmids.

Val-Calvo J, Luque-Ortega JR, Crespo I, Miguel-Arribas A, Abia D, Sánchez-Hevia DL, Serrano E, Gago-Córdoba C, Ares S, Alfonso C, Rojo F, Wu LJ, Boer DR, Meijer WJJ.

Nucleic Acids Res. 2018 Dec 14;46(22):11910-11926. doi: 10.1093/nar/gky996.

28.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.

Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A.

Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6.

29.

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.

Prieto-Potin I, Montagut C, Bellosillo B, Evans M, Smith M, Melchior L, Reiltin W, Bennett M, Pennati V, Castiglione F, Bürrig KF, Cooper U, Dockhorn-Dworniczak B, Rossenbach C, Luna-Aguirre CM, Barrera-Saldaña HA, Machado JC, Costa JL, Yacobi R, Tabibian-Keissar H, Buglioni S, Ronchetti L, Douglas-Berger L, Dubbink HJ, Alorini M, Sabourin JC, Rojo F.

J Mol Diagn. 2018 Sep;20(5):664-676. doi: 10.1016/j.jmoldx.2018.05.008. Epub 2018 Jun 26.

PMID:
29959022
30.

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.

Ruiz-Borrego M, Jimenez B, Antolín S, García-Saenz JA, Corral J, Jerez Y, Trigo J, Urruticoechea A, Colom H, Gonzalo N, Muñoz C, Benito S, Caballero R, Bezares S, Carrasco E, Rojo F, Martín M.

Invest New Drugs. 2019 Feb;37(1):98-108. doi: 10.1007/s10637-018-0614-9. Epub 2018 Jun 9.

PMID:
29948356
31.

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Aug;20(8):1093-1095. doi: 10.1007/s12094-018-1909-1.

PMID:
29916189
32.

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.

Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, García-Albéniz X, Maurel J.

Neoplasia. 2018 Jul;20(7):678-686. doi: 10.1016/j.neo.2018.05.004. Epub 2018 May 26.

33.

Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.

Torrejón B, Cristóbal I, Caramés C, Prieto-Potín I, Chamizo C, Santos A, Sanz-Alvarez M, Serna-Blasco R, Luque M, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

World J Surg. 2018 Nov;42(11):3771-3778. doi: 10.1007/s00268-018-4684-9.

PMID:
29796729
34.

Dissecting the therapeutic implications of the complex SMAD4 regulatory network in metastatic colorectal cancer.

Cristóbal I, Torrejón B, Santos A, Luque M, Sanz-Alvarez M, Rojo F, García-Foncillas J.

Eur J Surg Oncol. 2018 Aug;44(8):1283-1284. doi: 10.1016/j.ejso.2018.04.021. Epub 2018 May 9. No abstract available.

PMID:
29778618
35.

Potential Therapeutic Impact of miR-145 Deregulation in Colorectal Cancer.

Cristóbal I, Sanz-Alvarez M, Torrejón B, Santos A, Luque M, Rojo F, García-Foncillas J.

Mol Ther. 2018 Jun 6;26(6):1399-1400. doi: 10.1016/j.ymthe.2018.05.008. Epub 2018 May 18. No abstract available.

36.

Influence of the Hfq and Crc global regulators on the control of iron homeostasis in Pseudomonas putida.

Sánchez-Hevia DL, Yuste L, Moreno R, Rojo F.

Environ Microbiol. 2018 Oct;20(10):3484-3503. doi: 10.1111/1462-2920.14263. Epub 2018 Aug 5.

PMID:
29708644
37.

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Aug;20(8):990. doi: 10.1038/s41556-018-0052-0.

PMID:
29674681
38.

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.

Chin SF, Santonja A, Grzelak M, Ahn S, Sammut SJ, Clifford H, Rueda OM, Pugh M, Goldgraben MA, Bardwell HA, Cho EY, Provenzano E, Rojo F, Alba E, Caldas C.

Exp Mol Pathol. 2018 Jun;104(3):161-169. doi: 10.1016/j.yexmp.2018.03.006. Epub 2018 Mar 31.

39.

[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-López I, Cortés J, García-Caballero T, Martín M, López-García MÁ, Colomer R.

Rev Esp Patol. 2018 Apr - Jun;51(2):97-109. doi: 10.1016/j.patol.2017.12.002. Epub 2018 Mar 14. Spanish.

PMID:
29602380
40.

Comment on 'MicroRNA-199b-5p attenuates TGF-β1-induced epithelial-mesenchymal transition in hepatocellular carcinoma'.

Cristóbal I, Santos A, González S, Luque M, Torrejón B, Rojo F, García-Foncillas J.

Br J Cancer. 2018 Apr;118(7):1028-1029. doi: 10.1038/s41416-018-0013-1. Epub 2018 Mar 19. No abstract available.

41.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.

42.

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Feb;20(2):211-221. doi: 10.1038/s41556-017-0021-z. Epub 2018 Jan 22. Erratum in: Nat Cell Biol. 2018 Apr 19;:.

PMID:
29358704
43.

Potential contribution of SET and c-MYC deregulation to promote extracellular matrix remodelling in hepatocellular carcinoma.

Cristóbal I, Torrejón B, Rojo F, García-Foncillas J.

Br J Pharmacol. 2018 Feb;175(3):573-574. doi: 10.1111/bph.14108. Epub 2018 Jan 5. No abstract available.

44.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Jul;20(7):815-826. doi: 10.1007/s12094-017-1800-5. Epub 2017 Dec 22. Review. Erratum in: Clin Transl Oncol. 2018 Jun 18;:.

45.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M.

Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. Review.

46.

DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells.

Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R, Lopez-Magallon S, Esteban Rodriguez I, Dopazo A, Rojo F, Belda C, Alvarez R, Valentin J, Benitez J, Perona R, De Castro J, Ibanez de Caceres I.

Theranostics. 2017 Sep 22;7(17):4118-4134. doi: 10.7150/thno.20112. eCollection 2017.

47.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J.

Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279. Epub 2017 Nov 9.

48.

Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.

Manso R, Sánchez-Beato M, González-Rincón J, Gómez S, Rojo F, Mollejo M, García-Cosio M, Menárguez J, Piris MA, Rodríguez-Pinilla SM.

Br J Haematol. 2018 Nov;183(3):497-501. doi: 10.1111/bjh.14984. Epub 2017 Oct 26. No abstract available.

PMID:
29076126
49.

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.

Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, Guerrero Á, Trigo JM, Muñoz M, Pandiella A, Diego NG, Bezares S, Caballero R, Carrasco E, Urruticoechea A.

Oncotarget. 2017 Apr 14;8(42):73144-73153. doi: 10.18632/oncotarget.17113. eCollection 2017 Sep 22.

50.

Differential expression of the three Alcanivorax borkumensis SK2 genes coding for the P450 cytochromes involved in the assimilation of hydrocarbons.

Sevilla E, Yuste L, Moreno R, Rojo F.

Environ Microbiol Rep. 2017 Dec;9(6):797-808. doi: 10.1111/1758-2229.12598. Epub 2017 Nov 9.

PMID:
29052944

Supplemental Content

Support Center